Nykode Therapeutics AS

OB:NYKD Stock Report

Market Cap: NOK 943.1m

Nykode Therapeutics Future Growth

Future criteria checks 2/6

Nykode Therapeutics's earnings are forecast to decline at 10% per annum while its annual revenue is expected to grow at 21.8% per year. EPS is expected to decline by 3.6% per annum. Return on equity is forecast to be -103.3% in 3 years.

Key information

-10.0%

Earnings growth rate

-3.6%

EPS growth rate

Biotechs earnings growth16.8%
Revenue growth rate21.8%
Future return on equity-103.3%
Analyst coverage

Low

Last updated04 Dec 2024

Recent future growth updates

Recent updates

We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate

Aug 05
We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate

Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Mar 02
Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)

Jan 22
Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)

We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth

Aug 20
We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth

Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business

Apr 06
Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business

Earnings and Revenue Growth Forecasts

OB:NYKD - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20260-53-49-533
12/31/20254-41-28-434
12/31/20244-51-58-584
9/30/20244-37-87-87N/A
6/30/20247-38-88-87N/A
3/31/202411-40-92-91N/A
12/31/202313-35-99-97N/A
9/30/202315-42-63-61N/A
6/30/202313-47-57-55N/A
3/31/202311-46-53-52N/A
12/31/20229-43-23-21N/A
9/30/202238-20811N/A
6/30/202238-121114N/A
3/31/202236-101517N/A
12/31/202136-901N/A
9/30/2021219147174174N/A
6/30/2021218146174174N/A
3/31/2021216146178178N/A
12/31/2020216150180180N/A
9/30/20201-24-17-16N/A
6/30/20201-19-14-14N/A
3/31/20201-15-11-11N/A
12/31/20191-14-11-10N/A
9/30/20191-9-10-9N/A
6/30/20191-9-9-9N/A
3/31/20191-8-8-8N/A
12/31/20181-7-7-7N/A
9/30/20182-7N/AN/AN/A
6/30/20181-5N/AN/AN/A
3/31/20181-5N/AN/AN/A
12/31/20171-4N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NYKD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NYKD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NYKD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NYKD's revenue (21.8% per year) is forecast to grow faster than the Norwegian market (2.2% per year).

High Growth Revenue: NYKD's revenue (21.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: NYKD is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 08:44
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nykode Therapeutics AS is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Viktor SundbergABG Sundal Collier Sponsored
Geir HolomDNB Markets
Patrick TrucchioH.C. Wainwright & Co.